Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia


Sevinc A., ÖZKAN M., Ozet A., DANE F., Oksuzoglu B., Isikdogan A., ...More

ONCOTARGETS AND THERAPY, vol.11, pp.419-426, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 11
  • Publication Date: 2018
  • Doi Number: 10.2147/ott.s106342
  • Journal Name: ONCOTARGETS AND THERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.419-426
  • Keywords: chemotherapy, febrile neutropenia, neutrophil, ANC recovery, supportive care, myelosuppressive, COLONY-STIMULATING FACTOR, NON-HODGKINS-LYMPHOMA, FEBRILE NEUTROPENIA, G-CSF, RECEIVING CHEMOTHERAPY, CANCER-CHEMOTHERAPY, BREAST-CANCER, LUNG-CANCER, RISK, CHOP
  • Karadeniz Technical University Affiliated: Yes

Abstract

Background: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim in patients with chemotherapy-induced neutropenia.